Fatal Septic Pneumonia Case Reported in Bristol-Myers' Breakfree-2 MS CAR-T Study
BMY sits 45% above its 52-week low of $42.52 on light trading volume (0.3× avg).
Summary
Bristol-Myers presented Phase 1 Breakfree-2 data for zolacabtagene autoleucel (BMS-986353) in highly active relapsing and progressive multiple sclerosis at MSToronto 2026, and disclosed that one haRMS patient had a fatal event of septic pneumonia after the data cutoff. The death is a safety flag for the same autologous CAR-T platform the company already paused in autoimmune disease — the Zola-Cel program was halted in early June over life-threatening ICANS. That prior pause makes this fatality more than a routine trial footnote: it reinforces a safety pattern around the company's cell therapy push in immune indications. Bristol-Myers is a large, diversified pharma, so a single Phase 1 patient event won't reset the thesis, but it raises the bar for the program's risk-benefit case and invites scrutiny of the full Breakfree-2 safety dataset.
At the time of this announcement, BMY was trading at $61.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $125.7B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.